Hypothesis Comparison

⚛ Collide these ⚔ Judge as Duel

Comparing 2 hypotheses side-by-side

|

LRRK2 Kinase Inhibition Reduces α-Synuclein Spread via Lysosomal Enhancement

LRRK2 · neurodegeneration · -
Composite
0.620
Price
$0.62
Evidence For
0
Evidence Against
0

LRRK2 G2019S gain-of-function mutation hyperactivates kinase activity, dysregulating RAB GTPases and impairing lysosomal function, permitting α-synuclein oligomer accumulation. LRRK2 inhibitors (BIIB122, DNL151) restore lysosomal acidification and clearance. Major barriers include NHP lung toxicity findings requiring reformulation, incomplete penetrance of G2019S in humans, and minimal spontaneous α-synuclein pathology in G2019S knock-in mice without additional stressors.

G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying ly

LRRK2 · neurodegeneration · -
Composite
0.790
Price
$0.79
Evidence For
0
Evidence Against
0

The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact. In this view, mutant cells begin from a higher activity floor, and the key experimental discriminator is whether baseline-normalized EC50, slope, or Emax materially increase during graded swelling.

Convergent vs Divergent Predictions

This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.

LRRK2Lysosomalneurodegeneration
Convergent signals
  • LRRK2 recurs across 2 selected hypotheses with aligned directionality in lysosomal.
Divergent signals
  • No direct polarity conflicts detected among the selected hypotheses.

Verdict Summary

3/11
dimensions won
LRRK2 Kinase Inhibition Reduces α-Synucl
9/11
dimensions won
G2019S primarily raises baseline LRRK2 k

Radar Chart — 10 Dimensions

Score Comparison Bars

Mechanistic
0.65
0.86
Evidence
0.75
0.32
Novelty
0.55
0.48
Feasibility
0.55
0.91
Impact
0.78
0.88
Druggability
0.80
0.93
Safety
0.48
0.67
Competition
0.70
0.72
Data
0.70
0.82
Reproducible
0.68
0.80
KG Connect
0.50
0.50

Score Breakdown

DimensionLRRK2 Kinase Inhibition ReduceG2019S primarily raises baseli
Mechanistic0.6500.860
Evidence0.7500.320
Novelty0.5500.480
Feasibility0.5500.910
Impact0.7800.880
Druggability0.8000.930
Safety0.4800.670
Competition0.7000.720
Data0.7000.820
Reproducible0.6800.800
KG Connect0.5000.500

Evidence

LRRK2 Kinase Inhibition Reduces α-Synuclein Spread via Lysos

No evidence citations yet

G2019S primarily raises baseline LRRK2 kinase activity rathe

No evidence citations yet

Debate Excerpts

LRRK2 Kinase Inhibition Reduces α-Synuclein Spread

4 rounds · quality: 0.77

Theorist

# Therapeutic Hypotheses in Neurodegeneration --- ## Hypothesis 1: TREM2 Microglial Activation as Therapeutic Target in Alzheimer's Disease **Title:** Enhancing TREM2-dependent microglial phagocyto...

Skeptic

# Critical Evaluation of Neurodegeneration Therapeutic Hypotheses --- ## Hypothesis 1: TREM2 Microglial Activation **Original Confidence: 0.78 → Revised: 0.62** ### Weak Links - **Dose-dependency a...

Domain Expert

# Feasibility Assessment: Neurodegeneration Therapeutic Hypotheses ## Analytical Framework This assessment evaluates each hypothesis across five domains: 1. **Druggability** — tractability of the ta...

Synthesizer

{ "ranked_hypotheses": [ { "title": "C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD", "description": "Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat e...

G2019S primarily raises baseline LRRK2 kinase acti

4 rounds · quality: 0.74

Theorist

1. **Title:** `G2019S raises the LRRK2 kinase floor more than the swelling gain` **Mechanism:** G2019S may primarily increase constitutive catalytic output, producing higher baseline pRab10/pRa...

Skeptic

**Skeptical Read** The main weakness across all six is the same: most cited evidence shows that mutant `LRRK2` can elevate phospho-Rab output or alter lysosomal remodeling, but it does **not** cleanl...

Domain Expert

As of **April 24, 2026**, the hypotheses that most credibly survive are: 1. **#1 Higher baseline kinase activity more than higher swelling gain** 2. **#4 Amplification is context-dependent and strong...

Synthesizer

{ "ranked_hypotheses": [ { "title": "G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain", "description": "The most supported model ...

Price History Overlay